Fibrosis firsts

Why Cowen, Menlo chose Pliant as their first fibrosis investments

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments.

Cowen led Pliant’s untranched $62 million series B round on Monday, joined by fellow new investors Eventide Asset Management, Schroder

Read the full 434 word article

User Sign In